Home Cart Sign in  
Chemical Structure| 2097132-94-8 Chemical Structure| 2097132-94-8

Structure of Pralsetinib
CAS No.: 2097132-94-8

Chemical Structure| 2097132-94-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Blu667 is a highly potent and selective RET inhibitor with IC50 value of 0.4nM.

Synonyms: BLU-667; CS 3009; Gavreto

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pralsetinib

CAS No. :2097132-94-8
Formula : C27H32FN9O2
M.W : 533.60
SMILES Code : O=C([C@@]1(OC)CC[C@@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C
Synonyms :
BLU-667; CS 3009; Gavreto
MDL No. :MFCD31810155
InChI Key :GBLBJPZSROAGMF-SIYOEGHHSA-N
Pubchem ID :129073603

Safety of Pralsetinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Pralsetinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
UM-SCC-47 cells 15 nM 48 hours To evaluate the effect of Pralsetinib on the viability of UM-SCC-47 spheroids, results showed that Pralsetinib reduced cell viability and induced differentiation gene expression. Cancer Res. 2022 Sep 2;82(17):3143-3157.
SCC4 cells 15 nM 48 hours To evaluate the effect of Pralsetinib on the viability of SCC4 spheroids, results showed that Pralsetinib reduced cell viability and induced differentiation gene expression. Cancer Res. 2022 Sep 2;82(17):3143-3157.
SCCIC1 cells 15 nM 48 hours To evaluate the effect of Pralsetinib on the viability of SCCIC1 spheroids, results showed that Pralsetinib reduced cell viability and induced differentiation gene expression. Cancer Res. 2022 Sep 2;82(17):3143-3157.
A431 cells 15 nM 48 hours To evaluate the effect of Pralsetinib on the viability of A431 spheroids, results showed that Pralsetinib reduced cell viability and induced differentiation gene expression. Cancer Res. 2022 Sep 2;82(17):3143-3157.
MCF7 cells 500 nmol/L 48 hours To evaluate the inhibitory effect of Pralsetinib on ESR1 fusion-driven cell growth, results showed that Pralsetinib significantly inhibited the growth of MCF7 cells. Cancer Res. 2023 Oct 2;83(19):3237-3251.
T47D cells 500 nmol/L 48 hours To evaluate the inhibitory effect of Pralsetinib on ESR1 fusion-driven cell growth, results showed that Pralsetinib significantly inhibited the growth of T47D cells. Cancer Res. 2023 Oct 2;83(19):3237-3251.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SHO mice TPC1-derived TSR tumor model Oral gavage 30 mg/kg Once daily for 7 days Evaluate the inhibitory effect of BLU667 combined with Aurora or MEK1/2 kinase inhibitors on TSR tumors, showing that combination therapy significantly reduces tumor volume. Drug Resist Updat. 2023 May;68:100958.
NCG mice A431 subcutaneous xenograft model Peritumoral injection 48 mg/kg Once daily for 12 days To evaluate the inhibitory effect of Pralsetinib on the growth of A431 xenografts, results showed that Pralsetinib significantly inhibited tumor growth and induced differentiation. Cancer Res. 2022 Sep 2;82(17):3143-3157.
SCID/beige mice WHIM18 PDX model Oral 30 mg/kg bw per day Daily administration until study endpoint To evaluate the inhibitory effect of Pralsetinib on ESR1 fusion-driven tumor growth, results showed that Pralsetinib significantly inhibited the growth of WHIM18 PDX tumors. Cancer Res. 2023 Oct 2;83(19):3237-3251.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03037385 RET-altered Non Small Cell Lun... More >>g Cancer Medullary Thyroid Cancer RET-altered Papillary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors Less << Phase 1 Recruiting March 2023 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.37mL

1.87mL

0.94mL

18.74mL

3.75mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories